Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

By E. Van Cutsem, C. Köhne, E. Hitre, J. Zaluski, Chung-Rong Chang Chien, A. Makhson, G. D'Haens, T. Pintér, R. Lim, G. Bodoky and 8 more. New England Journal of Medicine, 2009

3,578 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/49a2d8873524100841296a181a3c3d429c53de92

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Fortunato Ciardiello
2. Lloyd J. Old
3. Carlos L. Arteaga
4. J. Engelman
5. J. Wolchok

Citations in the corpus

• New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “oped anti-CD20 antibodies ofatumumab and obinutuzumab [3, 4] and in rare cases of solid cancer patients after administration of cetuximab or trastuzumab [5, 6].”
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. (2010, background): “Retrospective analyses of phase II and III studies have demonstrated that KRAS mutations are predictive of resistance to anti-EGFR therapies; patients with mCRC with mutant (MT) KRAS tumor status do not derive clinical benefit.(8,14-19) We conducted this global, phase III trial to evaluate the effec”
• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017, methodology): “Study Design and Patients The CRYSTAL and FIRE-3 study designs, treatment parameters, andeligibilitycriteriahavebeenpreviously reported.(1-4)”
• Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, background): “Combining cetuximab therapy with folinic acid, 5-fluorouracil and irinotecan ( FOLFIRI chemotherapy ) has been shown to prolong progression-free survival in patients with metastatic colon cancer, whose tumours harbour wild-type KRAS allele”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “(2) FOLFIRI(6) [34, 35] ± bevacizumab [36, 37] (3) FOLFOX ± cetuximab/panitumumab [38, 39] (4) FOLFIRI ± cetuximab/panitumumab [40, 41] (5) 5-FU ? LV [42] ± bevacizumab [43, 44] or UFT ? LV [45] FOLFIRI bevacizumab* or CPT-11”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, methodology): “was observed in the CRYSTAL study evaluating FOLFIRI+/- cetuxumab in the same clinical setting [63-65].”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, result): “Cetuximab has been shown to improve the RR and median PFS and OS rates in first line in combination with FOLFIRI when compared with FOLFIRI alone in mCRC patients with RAS wild-type tumours [43, 44, 49] [I, B].”